Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Managing menopause.
Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W; MENOPAUSE AND OSTEOPOROSIS WORKING GROUP. Reid R, et al. Among authors: wolfman w. J Obstet Gynaecol Can. 2014 Sep;36(9):830-833. doi: 10.1016/S1701-2163(15)30487-4. J Obstet Gynaecol Can. 2014. PMID: 25222364 English, French.
Recommended measurement instruments for genitourinary symptoms associated with menopause: the COMMA (Core outcomes in menopause) consortium.
Paramanandam VS, Lensen S, Gabes M, Kann G, Donhauser T, Waters NF, Li AD, Peate M, Susanto NS, Caughey LE, Rangoonwal F, Liu J, Condron P, Obalowu IA, Archer DF, Bell RJ, Christmas M, Davies M, Davis SR, Giblin K, Iliodromiti S, Jaisamrarn U, Khandelwal S, Kiesel L, Aggarwal N, Mitchell CM, Mishra GD, Nappi RE, Panay N, Roberts H, Rozenberg S, Shifren J, Simon JA, Stute P, Vincent AJ, Wolfman W, Hickey M. Paramanandam VS, et al. Among authors: wolfman w. Menopause. 2024 May 14. doi: 10.1097/GME.0000000000002369. Online ahead of print. Menopause. 2024. PMID: 38743907
Recommended measurement instruments for menopausal vasomotor symptoms: the COMMA (Core Outcomes in Menopause) consortium.
Lensen S, Paramanandam VS, Gabes M, Kann G, Donhauser T, Waters NF, Li AD, Peate M, Susanto NS, Caughey LE, Rangoonwal F, Liu J, Condron P, Anagnostis P, Archer DF, Avis NE, Bell RJ, Carpenter JS, Chedraui P, Christmas M, Davies M, Hillard T, Hunter MS, Iliodromiti S, Jaff NG, Jaisamrarn U, Joffe H, Khandelwal S, Kiesel L, Maki PM, Mishra GD, Nappi RE, Panay N, Pines A, Roberts H, Rozenberg S, Rueda C, Shifren J, Simon JA, Simpson P, Siregar MFG, Stute P, Garcia JT, Vincent AJ, Wolfman W, Hickey M. Lensen S, et al. Among authors: wolfman w. Menopause. 2024 Apr 30. doi: 10.1097/GME.0000000000002370. Online ahead of print. Menopause. 2024. PMID: 38688464
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C, Lee M, Santoro N. Johnson KA, et al. Among authors: wolfman w. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1981-1997. doi: 10.1210/clinem/dgad058. J Clin Endocrinol Metab. 2023. PMID: 36734148 Free PMC article. Clinical Trial.
The 2022 hormone therapy position statement of The North American Menopause Society.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. Menopause. 2022 Jul 1;29(7):767-794. doi: 10.1097/GME.0000000000002028. Menopause. 2022. PMID: 35797481
79 results